Chugai Pharmaceutical Co., Ltd. (CHGCF)

32,43 0,00 (0,00%) Börsenschluss: 03:40PM EDT

Chugai Pharmaceutical Co., Ltd.

2-1-1 Nihonbashi-Muromachi
Chuo 103-8324
Japan
81 3 3281 6611
https://www.chugai-pharm.co.jp

Sektor(en): Healthcare
Branche: Drug Manufacturers - General
Vollzeitmitarbeiter: 7.604

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Osamu Okuda	President, CEO & Representative Director	1,42M	N/A	1963
Mr. Iwaaki Taniguchi	Executive VP, Head of Finance Supervisory Div., CFO & Director	N/A	N/A	1967
Toshiya Sasai	Executive of Investor Relations Group & Corporate Communications Department	N/A	N/A	N/A
Mr. Masayoshi Higuchi	VP and Head of Quality, Regulatory Compliance Unit, Business Strategy & Compliance Dept.	N/A	N/A	N/A
Mr. Shinji Hidaka	Executive Vice President	N/A	N/A	N/A
Mr. Junichi Ebihara	Executive Vice President	N/A	N/A	N/A
Dr. Yoshiaki Ohashi	SVP & Full-time Audit Supervisory Board Member	N/A	N/A	1960
Mr. Tetsuya Yamaguchi	Executive VP & Head of PHC Solution Unit	N/A	N/A	N/A
Mr. Yoshiyuki Yano	Executive Vice President	N/A	N/A	N/A
Dr. Shigehiro Yamada Ph.D.	Head of Sustainability Department and Full-Time Audit & Supervisory Board Member	N/A	N/A	1964

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Corporate Governance

Chugai Pharmaceutical Co., Ltd.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 5. Die grundlegenden Scores sind Audit: 1, Vorstand: 7, Shareholderrechte: 2, Kompensation: 1.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.